OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 03:49:57 2024-06-06 EDT | ||
| 27.53 EUR | -0.76% |
|
| Current month | +9.51% | ||
| 1 month | +34.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 27.53 | -0.76% |
| 24-06-05 | 27.74 | +2.97% |
| 24-06-04 | 26.94 | +2.86% |
| 24-06-03 | 26.19 | +3.40% |
| 24-05-31 | 25.33 | +5.59% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 03:49 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UWH |
| ISIN | DE000SF7UWH4 |
| Date issued | 2021-08-18 |
| Strike | 181.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.74 € |
|---|---|
| Lowest since issue | 2.42 € |
| Spread | 0.27 € |
| Spread % | 0.97% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
